These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 29510896

  • 1. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software.
    Nightingale G, Pizzi LT, Barlow A, Barlow B, Jacisin T, McGuire M, Swartz K, Chapman A.
    J Geriatr Oncol; 2018 Sep; 9(5):526-533. PubMed ID: 29510896
    [Abstract] [Full Text] [Related]

  • 2. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C.
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [Abstract] [Full Text] [Related]

  • 3. Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors.
    Oliveira RF, Oliveira AI, Cruz AS, Ribeiro O, Afreixo V, Pimentel F.
    BMC Geriatr; 2024 Jun 25; 24(1):557. PubMed ID: 38918696
    [Abstract] [Full Text] [Related]

  • 4. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
    Kim SH, Suh Y, Ah YM, Jun K, Lee JY.
    Support Care Cancer; 2020 Aug 25; 28(8):3617-3626. PubMed ID: 31802250
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.
    van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, de Man F, Piran F, Vincenten I, Jager A, Rijneveld AW, Brugma JD, Mathijssen RHJ, van Gelder T.
    Ann Oncol; 2015 May 25; 26(5):992-997. PubMed ID: 25628444
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer.
    Nightingale G, Hajjar E, Guo K, Komura S, Urnoski E, Sendecki J, Swartz K, Chapman A.
    J Geriatr Oncol; 2015 Sep 25; 6(5):411-7. PubMed ID: 26277113
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
    Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC, Lim SW, Salim A.
    Clin Ther; 2012 Aug 25; 34(8):1696-704. PubMed ID: 22795926
    [Abstract] [Full Text] [Related]

  • 12. Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study.
    Tavousi F, Sadeghi A, Darakhshandeh A, Moghaddas A.
    J Pediatr Hematol Oncol; 2019 Apr 25; 41(3):e146-e151. PubMed ID: 30531601
    [Abstract] [Full Text] [Related]

  • 13. Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved.
    Smithburger PL, Kane-Gill SL, Seybert AL.
    Int J Pharm Pract; 2012 Dec 25; 20(6):402-8. PubMed ID: 23134100
    [Abstract] [Full Text] [Related]

  • 14. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R, Lee EK, Berry SR, Saluja R, DeAngelis C, Giotis A, Emmenegger U.
    Eur J Clin Pharmacol; 2016 Nov 25; 72(11):1391-1399. PubMed ID: 27561266
    [Abstract] [Full Text] [Related]

  • 15. Drug-drug interactions in pediatric oncology patients.
    Balk TE, van der Sijs IH, van Gelder T, Janssen JJB, van der Sluis IM, van Leeuwen RWF, Engels FK.
    Pediatr Blood Cancer; 2017 Jul 25; 64(7):. PubMed ID: 28205376
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials.
    Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL.
    BMC Cancer; 2018 Nov 22; 18(1):1155. PubMed ID: 30466416
    [Abstract] [Full Text] [Related]

  • 17. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study.
    Jazbar J, Locatelli I, Horvat N, Kos M.
    Res Social Adm Pharm; 2018 Jun 22; 14(6):572-580. PubMed ID: 28716467
    [Abstract] [Full Text] [Related]

  • 18. Drug-drug interaction software in clinical practice: a systematic review.
    Roblek T, Vaupotic T, Mrhar A, Lainscak M.
    Eur J Clin Pharmacol; 2015 Feb 22; 71(2):131-42. PubMed ID: 25529225
    [Abstract] [Full Text] [Related]

  • 19. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study.
    Lin CF, Wang CY, Bai CH.
    Drugs Aging; 2011 Mar 01; 28(3):219-25. PubMed ID: 21250763
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.